- Coalition Comments to FDA re Labeling for Biosimilar Products (August 2016)
- Letter to State Dept re Intellectual Property & Access to Medicines (July 2016)
- Letter to Senate HELP Cmte Leaders re 21st Century Cures (May 2016)
- Coalition Comments to FDA re Direct-to-Consumer Advertising (April 2016)
- NPA Comments on FDA Generics Labeling to US House Appropriation and Agriculture Committees (April 2016)
- US TPP public health letter (April 2016)
- FOCR sign on letter regarding regulation of laboratory developed tests (LDT)_Senate (April 2016)
- FOCR sign on letter regarding regulation of laboratory developed tests (LDT)_House (April 2016)
- Non-Profit Groups Urge Obama Administrations, NIH to Lower Price of Government-Funded $129,000 Per Year Prostate Cancer Drug (March 2016)
- Comments of members of the Patient, Consumer, and Public Health Coalition on the FDA Draft Guidance entitled “Over-the-Counter Sunscreens: Safety and Effectiveness Data” (March 2016)
- Comments on Proposed Rule: Restricted Sale, Distribution, and Use of Sunlamp Products (March 2016)
- NPA comments re tanning beds, Docket ID FDA-2015-N-1765 (March 2016)
- NPA Recommends Enhancements to FDA’s Opioid Action Plan (Feb 2016)
- NPA Comments to Senator Murray re Senate HELP Preventable Tragedies Report (Jan 2016)
- NPA Comments re CDC Opioid Guidelines (Jan 2016)
- Comments of members of the Patient, Consumer, and Public Health Coalition on Medical Device Patient Labeling (October 2015)
- FedUP Coalition Letter to Senate Finance Committee (September 2015)
- Coalition Letter on 21st Century Cures draft legislation (May 2015)
- Letter Regarding Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (April 2015)
- Comments at the FDA Meeting to Discuss Proposed Rule that Would Allow Manufacturers of Generic Medications to Autonomously Update Their Product Label (March 2015)
- Letter in Support of the ACA and the Medical Device Tax (Jan 2015)
- Comments of members of the Patient, Consumer, and Public Health Coalition on the proposed order on Reclassification of Iontophoresis Devices Intended for Any Other Purposes (Dec 2014)
- Letter to Commissioner Hamburg re FDA Advisory Committees and Hearings (Dec 2014)
- Comments of members of the Patient, Consumer, and Public Health Coalition on the proposed order to reclassify External Pacemaker Pulse Generator devices and Pacing System Analyzers (Dec 2014)
- Chantix Petition (Oct 2014)
- NPA comments re Draft Guidance, “Intent to Exempt Certain Class II and Class I Reserved Medical Devices from Premarket Notification Requirements” (Oct 2014)
- NPA comments re the Proposed Rule, “Medical Device Classification Procedures” (Sept 2014)
- NPA comments re FDA draft guidance on correcting misinformation on social media (Sept 2014)
- Letter in support of the FDA’s proposed regulations to allow generic drug makers to initiate safety updates to their product labels(Sept 2014)
- Draft guidance for industry on distributing scientific and medical publications on risk information for approved prescription drugs and biologic products (August 2014)
- Comment on the FDA’s proposed rules to extend its authority to regulate electronic cigarettes under the Tobacco Control Act (August 2014)
- Letter to Congressman Cooper re Research for All Act (June 2014)
- Letter to House Appropriations Chair & Ranking Member re opposition to Cigar Exemption from FDA regulation (May 2014)
- Comments on Voluntary 2015 Edition Electronic Health Record Certification Criteria: Interoperability Updates and Regulatory Improvements (April 2014)
- Letter to Dr Hamburg re HPV Test (April 2014)
- Letter in support of the unique device identifier (UDI) in claims transmissions (March 2014)
- Letter of support for Congresswoman Slaughter’s antibiotics bill(March 2014)
- NPA Letter opposing the Antibiotic Development to Advance Patient Treatment Act of 2013 (ADAPT), H.R. 3742, to members of U.S. House Energy & Commerce Sub Committee on Health, and U.S. Senate Health, Education, Labor & Pension Committee (Feb2014)
- Comments to FDA re proposed changes to labeling for approved drugs & biologics (Feb2014)
- Letter to Congresswoman Rosa DeLauro in support of strengthening FDA safeguards (Feb 2014)
- Comments submitted to FDA re draft guidance on pharmacy compounding (Feb 2014)
- Letter submitted to FDA re: Proposing Labeling Changes for Approved Drugs and Biological Products (January 2014)
- Letter submitted to FDA re: down-classification of cardiac device (September 2013)
- Comments submitted to FDA re: antibacterial drug development (Aug 2013)
- Comments submitted to FDA re: risk categorization of cardiac devices (Aug 2013)
- Comments submitted to FDA re: proposed Alternative Pathway for Drug Approvals (Jan 2013)
- Letter to FDA in support of Unique Device Identifier system (Nov 2012)
- Letter to FDA Commissioner re Conflict of Interest Restrictions for advisory panels (Aug 2011)
- Letter to FDA re: Medical Device User Fee Act reauthorization process (Jul 2011)
Barbara Meier schreibt seit vielen Jahren für die NPAlliance Ratgeber und Testberichte. Dabei legt sie großen Wert auf die Ausführlichkeit sowie Richtigkeit ihrer Artikel. Sie zählt zu den wenigen Experten in ihrem Gebiet und hat sich über die letzten Jahren einen Namen in der Gesundheitsbranche gemacht.